Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder

Table 3 SRS-2 length of sulforaphane (SF) exposure analysis

SRS variable	N	Intervention (SF)^a			PL (non-exposure)
SRS variable	N	F-statistic	p value	N	F-statistic	p value
Total score
7 weeks	38	1.64	0.209	21	9.95	0.005
15 weeks	34	11.64	< 0.001	17	5.40	0.017
22 weeks	19	6.12	0.006
30 weeks	14	6.17	0.009
Social awareness
7 weeks	38	1.39	0.247	21	0.13	0.724
15 weeks	34	8.12	0.001	17	1.16	0.339
22 weeks	19	6.88	0.004
30 weeks	14	6.46	0.008
Social cognition
7 weeks	38	0.02	0.879	21	8.40	0.009
15 weeks	34	3.26	0.052	17	4.58	0.028
22 weeks	19	3.31	0.047
30 weeks	14	5.34	0.015
Social communication
7 weeks	38	1.55	0.221	21	8.20	0.010
15 weeks	34	11.03	< 0.001	17	3.65	0.051
22 weeks	19	5.54	0.008
30 weeks	14	2.94	0.076
Social motivation
7 weeks	38	0.01	0.916	21	3.66	0.070
15 weeks	34	2.81	0.075	17	2.02	0.168
22 weeks	19	2.21	0.126
30 weeks	14	5.31	0.015
RRB^b
7 weeks	38	4.37	0.044	21	5.29	0.032
15 weeks	34	10.14	< 0.001	17	3.33	0.064
22 weeks	19	5.26	0.010
30 weeks	14	3.85	0.038
SCI^c
7 weeks	38	0.67	0.417	21	9.56	0.006
15 weeks	34	10.78	< 0.001	17	4.59	0.028
22 weeks	19	6.21	0.005
30 weeks	14	7.38	0.005

Bold signifies p < 0.05
MANOVA test for repeated measures used (compared to baseline at 0 weeks)
^aN for SF group at 7 and 15 weeks includes participants from the initial PL group while they were on SF at 22 and 30 weeks (their first 7 and 15 weeks of exposure)
^bRestricted interests and repetitive behavior
^cSocial communication and interaction

ISSN: 2040-2392